| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/19/2011 | US7927596 Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides |
| 04/19/2011 | US7927595 Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies |
| 04/19/2011 | US7927594 Monoclonal antibody 9TL that comprises an Fc region having impaired effector function; treating a disease characterized by aberrant deposition of a protein in the brain of a subject; Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy |
| 04/19/2011 | US7927593 TGF-beta binding antibodies |
| 04/19/2011 | US7927592 Method of inhibiting complement activation |
| 04/19/2011 | US7927591 Protein; an immunoglobulin heavy chain variable domain sequence and an immunoglobulin light chain variable domain sequence forming an antigen binding site; inhibiting a binding interaction between aLFA-1 and a cognate ligand of aLFA-; inflammatory disorders |
| 04/19/2011 | US7927590 Compositions and methods for inhibiting growth of smad4-deficient cancers |
| 04/19/2011 | US7927586 Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli |
| 04/19/2011 | US7927584 Enterococcus strain able surviving and colonizing the gastrointestinal tract of humans and/or animals, provide health benefit; antibiotic resistance, do not produce any gelatinase, DNase and decarboxylases; regulating the immune response; food preservatives |
| 04/19/2011 | US7927583 Receptor based antagonists and methods of making and using |
| 04/19/2011 | US7927580 Identifying new immunomodulatory chemical entities (NICE); reacting a candidate NICE with a Tat SH3 binding domain, identifying the bound candidate NICE and determining whether it induces monocytes to differentiate into dendritic cells (DC) or regulatory macrophages (AReg); drug screening; immunotherapy |
| 04/19/2011 | CA2478081C Multiple and multivalent dna vaccines in ovo |
| 04/19/2011 | CA2451680C Human dr4 antibodies and uses thereof |
| 04/19/2011 | CA2450203C Capsular polysaccharide solubilisation and combination vaccines |
| 04/19/2011 | CA2441099C Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases |
| 04/19/2011 | CA2422094C Vaccination method |
| 04/19/2011 | CA2378778C Il-16 antagonists |
| 04/19/2011 | CA2319599C Delivery of immunogenic molecules via hbsag particles |
| 04/19/2011 | CA2282790C Chimeric flavivirus vaccines |
| 04/19/2011 | CA2195090C Lkp pilin structural genes and operon of nontypable haemophilus influenzae |
| 04/19/2011 | CA2189979C Improved modified live brsv vaccine |
| 04/19/2011 | CA2185859C Preparation of virally inactivated intravenously injectable immune serum globulin |
| 04/14/2011 | WO2011044576A2 Selectively disrupted whole-cell vaccine |
| 04/14/2011 | WO2011044570A2 Recombinant antibodies against h1n1 influenza |
| 04/14/2011 | WO2011044563A2 Il-17 family cytokine compositions and uses |
| 04/14/2011 | WO2011044561A1 Attenuated influenza viruses and vaccines |
| 04/14/2011 | WO2011044553A1 Anti-vla-4 related assays |
| 04/14/2011 | WO2011044542A1 Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| 04/14/2011 | WO2011044516A2 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 04/14/2011 | WO2011044499A2 Enterotoxigenic e. coli fusion protein vaccines |
| 04/14/2011 | WO2011044492A1 Methods of treatment and screening assays for hif-1alpha regulation |
| 04/14/2011 | WO2011044452A2 Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences |
| 04/14/2011 | WO2011044336A2 Human domain antibodies against components of the human insulin-like growth factor (igf) system |
| 04/14/2011 | WO2011044158A1 Immunopotentiator-linked oligomeric influenza immunogenic compositions |
| 04/14/2011 | WO2011044152A1 Protection against pandemic and seasonal strains of influenza |
| 04/14/2011 | WO2011044082A2 Compositions and methods for inhibiting madcam |
| 04/14/2011 | WO2011043830A2 Methods, agents and peptides for inducing an innate immune response in hiv vaccination |
| 04/14/2011 | WO2011043739A1 Methods and compositions for maintenance of a functional wound |
| 04/14/2011 | WO2011043584A2 Highly pathogenic avian influenza virus protein vaccine derived from transgenic plants, and method for preparing same |
| 04/14/2011 | WO2011043538A2 Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
| 04/14/2011 | WO2011042681A1 Staphylococcus aureus divi1b for use as vaccine |
| 04/14/2011 | WO2011042483A1 Antigenic peptides for the detection of chlamydia-related bacteria and tests of diagnosis |
| 04/14/2011 | WO2011042180A1 Generation of a broad t-cell response in humans against hiv |
| 04/14/2011 | WO2011042026A1 A cytolytic rtx-toxin from gallibacterium anatis |
| 04/14/2011 | WO2011041894A1 Siglec 15 antibodies in treating bone loss-related disease |
| 04/14/2011 | WO2011041886A1 Vaccines comprising heat-sensitive transgenes |
| 04/14/2011 | WO2011022706A3 Methods and compositions for treatment of pulmonary fibrotic disorders |
| 04/14/2011 | WO2011017791A9 Monoclonal antibodies against the pbp2-a protein and homologous sequences for the treatment of infections by and immunodiagnostics of bacteria of the firmicutes phylum |
| 04/14/2011 | WO2011003100A4 Compositions and methods for diagnosing and/or treating influenza infection |
| 04/14/2011 | WO2010117455A3 Human monoclonal antibodies protective against bubonic plaque |
| 04/14/2011 | WO2010096470A4 Method for inhibiting neurodegeneration |
| 04/14/2011 | WO2010033337A8 Rabies virus-based recombinant immunocontraceptive compositions and methods of use |
| 04/14/2011 | WO2010030979A3 Targeting pathogenic monocytes |
| 04/14/2011 | WO2009126705A8 Induction of tumor hypoxia for cancer therapy |
| 04/14/2011 | WO2001085798A9 Human monoclonal antibodies to dendritic cells |
| 04/14/2011 | US20110088104 Novel antibodies for the treatment of hiv |
| 04/14/2011 | US20110086437 Methods to inhibit cell growth |
| 04/14/2011 | US20110086422 Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
| 04/14/2011 | US20110086091 Stable crystal modifications of dopc |
| 04/14/2011 | US20110086067 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| 04/14/2011 | US20110086066 Methods to Increase Transgene Expression From Bacterial-Based Delivery Systems by Co-Expressing Suppressors of the Eukaryotic Type I Interferon Response |
| 04/14/2011 | US20110086065 Lentival Vector-Based Vaccine |
| 04/14/2011 | US20110086064 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 04/14/2011 | US20110086063 Vaccines for prevention and treatment of addiction |
| 04/14/2011 | US20110086062 Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| 04/14/2011 | US20110086061 Cancer Detection Methods and Reagents |
| 04/14/2011 | US20110086059 Non-hemolytic clya for excretion of proteins |
| 04/14/2011 | US20110086058 Immunopotentiator-Linked Oligomeric Influenza Immunogenic Compositions |
| 04/14/2011 | US20110086056 Methods for the early diagnosis of ovarian cancer |
| 04/14/2011 | US20110086055 Her2 peptides |
| 04/14/2011 | US20110086054 Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose |
| 04/14/2011 | US20110086053 Glycolipids And Analogues Thereof As Antigens For NKT Cells |
| 04/14/2011 | US20110086051 System and method for monitoring and optimizing immune status in transplant recipients |
| 04/14/2011 | US20110086050 Glycoprotein compositions |
| 04/14/2011 | US20110086049 Receptor Modulators |
| 04/14/2011 | US20110086048 Detection of human immunodeficiency virus co-receptor tropism in aviremic subjects |
| 04/14/2011 | US20110086047 Fc receptor homolog antibodies and uses thereof |
| 04/14/2011 | US20110086046 Treatment of MS with goat serum |
| 04/14/2011 | US20110086045 Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract |
| 04/14/2011 | US20110086044 Compositions and Methods to Inhibit HPV Infection |
| 04/14/2011 | US20110086043 STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES |
| 04/14/2011 | US20110086042 Centrosomal Proteins, Nucleic Acids and Method of Use Thereof |
| 04/14/2011 | US20110086041 Fusion-Intermediate State of HIV-1 gP41 Targeted by Broadly Neutralizing Antibodies |
| 04/14/2011 | US20110086040 Method of treating hemolytic disease |
| 04/14/2011 | US20110086039 Methods of Treating Liver Fibrosis and Pre-Cirrhosis with Epidermal Growth Factor Receptor Inhibitors |
| 04/14/2011 | US20110086038 Interleukin-13 Antibody Composition |
| 04/14/2011 | US20110086037 Method of treating inflammatory disorders |
| 04/14/2011 | US20110086036 Composition comprising vlp and amyloid beta peptide |
| 04/14/2011 | US20110086035 Immunotherapeutic methods and molecules |
| 04/14/2011 | US20110086034 Nucleotide and protein sequences of nogo genes and methods based thereon |
| 04/14/2011 | US20110086033 Method of inhibiting osteoclast activity |
| 04/14/2011 | US20110086032 Anti-fgf19 antibodies and methods using same |
| 04/14/2011 | US20110086031 Inhibition Of The Activity Of The Capsaicin Receptor In The Treatment Of Obesity Or Obesity-Related Diseases And Disorders |
| 04/14/2011 | US20110086030 Inhibition of cancer metastasis |
| 04/14/2011 | US20110086029 Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis |
| 04/14/2011 | US20110086028 Prevention of hiv infection |
| 04/14/2011 | US20110086027 Anti-cxcr4 antibodies |
| 04/14/2011 | US20110086026 Antibodies against il-13 receptor alpha 1 and uses thereof |
| 04/14/2011 | US20110086025 Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent |
| 04/14/2011 | US20110086024 Use of antagonists of the interaction between hiv gp120 and a4b7 integrin |